iPSC Differentiated Cardiomyocytes
Ready to use, beating Human cardiomyocytes differentiated from normal and diseased iPSCs: Perfect in vitro tool for electrophysiology and biochemical assays, preclinical cardiac safety assessment, drug development, toxicity screening and genetic studies.
Cardiomyocytes or cardiac muscle cells (also known as myocardiocytes or cardiac myocytes) are the muscle cells (myocytes) that make up the cardiac muscle. Due to the lack of natural source of cardiac cells, in vitro differentiated human cardiomyocytes have been proven as an essential tool not only for general cardiovascular research, as well as drug development and pre-clinical research 1, 2
These ASE-9027 iPSC-derived cardiomyocytes are terminally differentiated cells. They cannot be expanded in vitro. However, once seeded onto the culture vessels, they can be maintained as functional (beating) cells for at least 30 days, if the customer strictly follows our protocol.
The original (parental) iPSCs were derived from peripheral blood of a 59 yr old, Caucasian, male donor, using the episomal integration-free reprogramming method.
Applied StemCell, Inc. provides high purity (>90%), beating human iPSC-derived Cardiomyocytes (Video 1) that express typical markers of cardiomyocytes, e.g. TNNT/cTnT and α-Actinin (Figure 1) and are validated for functional viability by patch-clamp and Fluo-4TM Direct Calcium Assay (Video 2). ASC’s Cardiomyocytes can be used for electrophysiological and biochemical assays, for example, the effect of compounds on the heart rate can be assayed by impedance-based measurements (Figure 2).
The iPSC-derived cardiomyocytes are an essential tool for drug and toxicity screening, gain of function and loss of function genetic studies as well as preclinical studies. These functionally active cardiomyocytes can be used for preclinical cardiac safety assessment based on the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. They are ready to use, beating cells that have been derived from normal human PBMC grown in a feeder-free culture system.
Characterization of iPSC-differentiated Cardiomyocytes
Video 1: Beating iPSC-derived Cardiomyocytes
Figure 2. Beating rate of iPSC-derived cardiomyocytes measured with xCELLigence RTCA Cardio System (ACEA Biosciences and Roche Applied Science). Cells were treated with various dosages of Isoproterenol. (Left) Before Treatment (50 μM; 10 μM; 5 μM); (Right) 30 min after treatment (50 μM; 10 μM; 5 μM).
- Daily, N. J., et al. (2017). High-Throughput Phenotyping of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Neurons Using Electric Field Stimulation and High-Speed Fluorescence Imaging. ASSAY and Drug Development Technologies. 15(4): 178-188. https://doi.org/10.1089/adt.2017.781
- Daily, N. J., Santos, R., Vecchi, J., Kemanli, P., & Wakatsuki, T. (2017). Calcium transient assays for compound screening with human iPSC-derived cardiomyocytes: Evaluating new tools. Journal of evolving stem cell research, 1(2), 1.
- Daily, N. J., et al. (2015). Journal of Bioengineering & Biomedical Science, 2015.